By Editor • August 20, 2026 • 1 min read
Capricor Therapeutics' efforts to prevent FDA rejection of its Duchenne muscular dystrophy treatment appear futile, requiring a new clinical trial for approval.
Read moreBy Editor • August 20, 2026 • 1 min read
Despite challenges, my son prepares for his second year of graduate studies while facing uncertainty over Capricor's Duchenne muscular dystrophy treatment.
Read moreBy Editor • August 19, 2026 • 1 min read
The deaths in Chinese clinical trials have sparked concerns about the oversight and safety of experimental medicine in the country.
Read more
